Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 16;111(4_Suppl):22-32.
doi: 10.4269/ajtmh.23-0908. Print 2024 Oct 1.

Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial

Yaya I Coulibaly  1   2 , Abdoul F Diabate  1 , Moussa Sangare  1 , Sekou O Thera  1 , Housseini Dolo  1 , Salif S Doumbia  1 , Siaka Y Coulibaly  1 , Ayouba Diarra  1 , Lamine Diarra  1 , Diadje Tanapo  1 , Michel E Coulibaly  1 , Lamine Soumaoro  1 , Abdallah A Diallo  1 , Amatigue Zeguime  1 , Yacouba Sanogo  1 , Adama Berthe  1 , Fatoumata Dite Nene Konipo  1 , Charles Mackenzie  3   4 , Mariana Stephens  3 , Joseph P Shott  5 , Jayla Norman  3 , Ute Klarmann-Schulz  6 , Achim Hoerauf  6 , Andrew Majewski  3 , John Horton  7 , Sarah Sullivan  3 , Eric A Ottesen  3 , Thomas B Nutman  8
Affiliations
Randomized Controlled Trial

Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial

Yaya I Coulibaly et al. Am J Trop Med Hyg. .

Abstract

Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The protocol was approved by the Western Institutional Review Board (Olympia, WA) and additionally by the University of Sciences, Techniques and Technologies of Bamako’s local ethics committee (No2016/150/CE/FMPOS). Approval from the Ministry of Health was obtained for study drug importation and for trial implementation. Informed written consent was obtained from all individuals. Participants who could not read and understand French were assisted by a family member or another trusted person who could read and understand French. The role of this person was to read the information sheet and consent form and explain them to the participant. This person was also asked to sign the consent form as a witness. The participant’s fingerprint was placed on the consent form as his/her signature. ClinicalTrials.gov NCT02927496 was registered October 7, 2016 at https://clinicaltrials.gov/ct2/show/NCT02927496.

Authors’ contributions: Y. I. Coulibaly, A. F. Diabate, M. Sangare, E. A. Ottesen, A. Hoerauf, U. Klarmann-Schulz, S. Y. Coulibaly, S. S. Doumbia, M. Stephens, J. Horton, C. Mackenzie, and T. B. Nutman designed and conceived the study; Y. I. Coulibaly, E. A. Ottesen, C. Mackenzie, A. Hoerauf, U. Klarmann-Schulz, S. Sullivan, and T. B. Nutman approved the final version of the manuscript and helped with the analysis and drafting of the manuscript; Y. I. Coulibaly, A. F. Diabate, M. Sangare, S. O Thera, D. Tanapo, M. Stephens, H. Dolo, M. E. Coulibaly, L. Soumaoro, A. Zeguime, A. Diarra, U. Klarmann-Schulz, S. Sullivan, A. Majewski, and Y. Sanogo collected and processed the samples and drafted the manuscript; Y. I. Coulibaly, A. F. Diabate, M. Sangare, S. O Thera, D. Tanapo, M. Stephens, H. Dolo, M. E. Coulibaly, L. Soumaoro, U. Klarmann-Schulz, S. Sullivan, and Y. Sanogo managed the data, did the statistical analysis, and helped to draft the manuscript. All authors read and approved the final version of the manuscript.

Figures

Figure 1.
Figure 1.
Map of Mali showing the study sites.
Figure 2.
Figure 2.
Study implementation design showing the main time points. D = day; M = month.
Figure 3.
Figure 3.
Study flow chart. LE = lymphedema.
Figure 4.
Figure 4.
Dynamics of lymphedema changes in patients over the 24-month course of study. (A) Doxycycline treatment arm; (B) placebo treatment arm.
Figure 5.
Figure 5.
Reduction in lymphedema (LE) volume over the 24-month period of study. (A) Percentage of patients receiving placebo (blue) or doxycycline (red) showing reduction in LE volume. (B) Violin plots of percent changes in LE volume for both placebo (red) and doxycycline (blue) groups.
Figure 6.
Figure 6.
Changes in skin thickness (A) and leg circumference (B) over 24 months.
Figure 7.
Figure 7.
Acute adenolymphangitis (ADLA) attacks over the study period. (A) Reduction in number of ADLA attacks over study period. (B) Number of ADLA attacks experienced during each time period.
Figure 8.
Figure 8.
Adherence to hygiene measures over the 24 months of the study.
See this image and copyright information in PMC

References

    1. Chakraborty S, Gurusamy M, Zawieja DC, Muthuchamy M, 2013. Lymphatic filariasis: Perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis. Microcirculation 20: 349–364. - PMC - PubMed
    1. Stangl AL, Earnshaw VA, Logie CH, van Brakel WC, Simbayi L, Barré I, Dovidio JF, 2019. The health stigma and discrimination framework: A global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med 17: 31. - PMC - PubMed
    1. Asiedu SO, Kwarteng A, Amewu EKA, Kini P, Aglomasa BC, Forkuor JB, 2021. Financial burden impact quality of life among lymphatic filariasis patients. BMC Public Health 21: 174. - PMC - PubMed
    1. Clark J. et al., 2021. How modelling can help steer the course set by the World Health Organization 2021–2030 roadmap on neglected tropical diseases. Gates Open Res 5: 112. - PMC - PubMed
    1. Gyapong JO, Owusu IO, da-Costa Vroom FB, Mensah EO, Gyapong M, 2018. Elimination of lymphatic filariasis: Current perspectives on mass drug administration. Res Rep Trop Med 9: 25–33. - PMC - PubMed

Publication types

LinkOut - more resources